share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144：拟议出售证券
美股SEC公告 ·  08/07 13:36
Moomoo AI 已提取核心信息
Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 30,000 Class A shares of the company on 08/07/2024, with an aggregate market value of $213,000. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a three-month period where a total of 200,000 shares were sold for gross proceeds of $1,618,500.
Christopher Gibson, an officer and director at Recursion Pharmaceuticals, Inc., is set to sell 30,000 Class A shares of the company on 08/07/2024, with an aggregate market value of $213,000. These shares were originally acquired on 09/01/2016 as founders shares, a form of compensation from the issuer. This planned sale follows a three-month period where a total of 200,000 shares were sold for gross proceeds of $1,618,500.
Recursion Pharmaceuticals, Inc. 的一名官员和董事 Christopher Gibson 计划于 2024 年 08 月 07 日卖出公司的 30,000 股 A 类股份，市值总计 213,000 美元。 这些股份最初于 2016 年 09 月 01 日作为创始股份从发行人处获得，是一种形式的补偿。 计划出售的这批股份是在已经出售一批总计 200,000 股，获得总收益为 1,618,500 美元的三个月后。
Recursion Pharmaceuticals, Inc. 的一名官员和董事 Christopher Gibson 计划于 2024 年 08 月 07 日卖出公司的 30,000 股 A 类股份，市值总计 213,000 美元。 这些股份最初于 2016 年 09 月 01 日作为创始股份从发行人处获得，是一种形式的补偿。 计划出售的这批股份是在已经出售一批总计 200,000 股，获得总收益为 1,618,500 美元的三个月后。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息